US/UK/Canada

Share

Quotes

Our expanding portfolio of innovative, image-guided laser ablation solutions is designed to meet the new and challenging medical treatment requirements in the growing field of minimally invasive, interventional MR procedures.
Lars-Erik Eriksson, CEO of CLS
The Access-i software and the agreement with Siemens Healthineers is yet another step towards CLS’s goal to build the next generation of integrated, workflow-optimized solutions for precision ablation.
Dan Mogren, CCO at CLS
The Access-i software and the agreement with Siemens Healthineers is yet another step towards CLS’s goal to build the next generation of integrated, workflow-optimized solutions for precision ablation.
Dan Mogren, CCO at CLS
We are pleased and excited to continue our association with DMI as it demonstrates our relevance and effectiveness, in this area, compared with other leading products in the field of urology.
Dan Mogren, CCO
UTMB continues to choose our products for treatment of patients with early stage prostate cancer, or other tumor disease, in the prostate. UTMB has become an important reference for us in the USA-market and the collaboration with the hospital continues to develop in a positive way.
Dan Mogren, CCO
I am very pleased that Toronto General Hospital has chosen our products for its clinical study. We will in a systematic way get access to important data on how our products perform when used in MRI guided focal laser ablation treatment.
Lars-Erik Eriksson, CEO
It is very gratifying that UTMB choses to purchase our system and continue to use our products. Dr. Eric Walser has so far treated about 20 patients, with early stage prostate cancer, using CLS’ accessories for MR-guided focal laser ablation and the products are performing very well.
Dan Mogren, CCO
CLS’ goal for 2017, to initiate sales in the US market, has now been accomplished. We receive repeat orders from demanding customers. This indicates good marks for our products. In the long term I see huge opportunities for us to build a successful business in the US.
Dan Mogren, CCO
As previously announced two patients have received treatment. An image guided laser treatment procedure was carried out, aiming at reducing pain and decreasing /eliminating the vascular malformation, with an immediate positive outcome.
Dan Mogren, CCO at CLS
The relationship with UTMB and Dr. Eric Walser is important to us also in other ongoing discussions in the US. We believe that we are seeing the beginning of a commercial acceptance for our products’ features and pricing, and that we thereby are able to compete with bigger and more established suppliers within our market segment.
Dan Mogren, CCO at CLS
This is the first time we are part of this conference, targeting one of our main user groups, interventional oncologists. WCIO 2017 is an excellent forum for us to showcase our products and further expand our presence in the US market.
Dan Mogren, CCO at CLS
Pick a time period -
Tags ( Active)

Correction: Publication of CLS half-year report, 1 June – 30 June 2024

In the half-year report that was attached to the press release that was sent out today, August 23 at 8:51 a.m., two errors have been discovered, it has now been corrected by corrected pdf files being published on the company's website.The error was in the table of the consolidated cash flow on page 13; "Consolidated cash flow statement for the period". The incorrect version stated that:   1. The company's bridge loan of SEK 12.5 million was reported in the original report under "Cash paid to suppliers and employees" and not as "Proceeds from borrowings". 2. On the penultimate row

CLS publishes half-year report January – June 2024

Summary of the half-year report (relates to the Group) First semester (01/01/2024–06/30/2024)  · Net sales totaled SEK 8,762,000 (SEK 1,839,000). · Profit/loss after financial items totaled SEK -26,163,000 (SEK -37,980,000). · Basic and diluted earnings per share totaled SEK -0.02 (SEK -0.25). · The equity ratio on June 30, 2024, was 63% (-31%).  The second quarter (04/01/2024–06/30/2024)  · Net sales totaled SEK 5,622,000 (SEK 1,252,000). · Profit/loss after financial items totaled SEK -13,592,000 (SEK -16,516,000). · Basic and diluted earnings per share

CLS announces last day of trading with BTU and first day of trading in warrants of series TO 7

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE.   Clinical Laserthermia Systems AB:s ("CLS" or the “Company") rights issue is now registered with the Swedish Companies

CLS announces outcome of rights issue

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE. The subscription period in Clinical Laserthermia Systems AB AB (publ) ("CLS"or the "Company") rights issue of B-shares and warrants (

Communique from the Annual General Meeting on Friday June 28th in Clinical Laserthermia Systems AB

Today, June 28th 2024, is the Annual General Meeting (the “AGM”) of Clinical Laserthermia Systems AB, 556705-8903. Below is a summary of the decisions taken. All decisions were taken with the required majority.Adoption of the income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet (Item 8a) The AGM resolved to adopt the presented income statement and balance sheet as well as the consolidated income statement and consolidated balance sheet.   Resolution regarding appropriation of the company's profit according to the adopted

CLS enters the Italian market for Focal Laser Ablation together with the Nationwide Italian Company Tecnogamma s.r.l.

Lund, Sweden - Clinical Laserthermia Systems AB (publ) (CLS) today announced it has entered into an exclusive distribution agreement with Tecnogamma s.r.l. Company (Tecnogamma) to market and sell the CLS TRANBERG[®] product portfolio for urology in Italy.The interest for focal therapies is growing in Italy and as previously reported the first cases using the CLS TRANBERG® Thermal Therapy System in prostate cancer patients were performed in April 2024 at University Hospital San Luigi Gonzaga in Turin by Prof. Francesco Porpiglia, Head of the Urological division. CLS is now entering into an

Recruitment of Glioblastoma Patients to the CLS-sponsored Clinical Study at Skåne University Hospital is now Completed

Lund, Sweden – Clinical Laserthermia Systems AB (publ) (CLS or the "Company") today announces that the recruitment of patients to the clinical study, sponsored by CLS and co-funded by ClearPoint Neuro Inc, at Skåne University Hospital in Sweden is now completed. In the study a total of 14 patients with glioblastoma have been treated with MR-guided laser ablation.The study is a single-center, non-randomized prospective study with the aim of evaluating the safety and feasibility of minimally invasive MRI-guided laser ablation (also named as Laser Interstitial Thermal Therapy or LITT) of tumor

Clinical Laserthermia Systems publishes supplementary prospectus regarding ongoing rights issue

Clinical Laserthermia Systems AB (publ) (“CLS” or the ”Company”) has drafted a supplementary prospectus (the ”Supplementary Prospectus”) to the EU growth prospectus approved and registered by the Swedish Financial Supervisory Authority (SW: Finansinspektionen) on June 10, 2024 (the “Prospectus”). The Supplementary Prospectus has today, June 20, 2024, been approved and registered by the Swedish Financial Supervisory Authority.The Prospectus has been drafted in connection with the ongoing rights issue of units consisting of new B-shares and warrants of series TO 7 B, which was resolved by the

CLS receives additional order for ClearPoint Prism products corresponding to approximately SEK 7.5 million

Lund, Sweden – Clinical Laserthermia Systems AB (publ) ("CLS" or the "Company") today announces that the Company has received additional orders from ClearPoint Neuro, Inc (Nasdaq:CLPT). The order, which has a value of approximately SEK 7.5 million, is for ClearPoint Prism products and is part of ClearPoint Neuro's full market launch in North America, which began in early June this year, and follows previous orders that CLS received around the turn of the year 2023/2024 totaling approximately SEK 10.5 million.­­ CLS's collaboration with ClearPoint Neuro Inc aims to develop and

CLS publishes prospectus in connection with forthcoming rights issue

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE. The Board of Directors of Clinical Laserthermia Systems AB AB (publ) ("CLS" or the “Company”) announced on 30 May 2024 its

Clinical Laserthermia Systems publishes annual report for 2023

Lund, Sverige – Clinical Laserthermia Systems AB (publ) (“CLS” or “the company”) today published its annual report for fiscal year 2023.­­ Clinical Laserthermia Systems AB (publ) (“CLS” or “the company”) today published its annual report for fiscal year 2023. The report is available on the company’s website https://clinicallaser.se/. It is also attached to this press release.   An English version of the annual report will be published on the company’s website in the beginning of July.   Contact information: Dan J. Mogren, CEO, Clinical Laserthermia Systems AB (publ)Tel:

BioStock: CLS’ partner initiates full market release in the US

CLS’ commercial partner ClearPoint Neuro has initiated its full market release of the ClearPoint Prism 3T Neuro Laser Therapy System, which is based on CLS’ technology. The launch took place June 1-4 at the 2024 American Society for Stereotactic and Functional Neurosurgery Biennial Meeting in Nashville.Read the full article at biostock.se : https://www.biostock.se/en/2024/06/cls-partner-initiates-full-market-release-in-the-us/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

First Clinical Data from the Investigator-initiated study with CLS Focal Laser Ablation system at the University Hospital Magdeburg will be presented at the Nordkongress in Lübeck 13-15 June 2024

Lund, Sweden - CLS today announces that first clinical data from the PRO-FLA study (Fokale Laserablation (FLA) zur fokalen Behandlung des lokal begrenzten Prostata-karzinoms) using the CLS TRANBERG® Thermal Therapy system for focal laser ablation will be presented at the Nordkongress in Lübeck 13-15 June 2024. An abstract with the title “Ultrasound-guided Focal Laser Ablation in Localized Prostate Cancer within the Pro-FLA Study – Oncological outcome after 6 months” has been accepted for an oral presentation to be held 13 June.The presentation is part of the scientific program of the

CLS presents its new strategic direction in a Business Update Event on June 12

Lund, Sverige – Clinical Laserthermia Systems AB (publ) (CLS) recently announced a new strategic focus based on the opportunities within the neurosurgery segment. CLS welcomes investors, media, and the public to virtually attend a Live Business Update Event on June 12, 2024, at 9.30 CEST.­­ During the event, the company will give an update on the recently announced strategic focus on neurosurgery. Special attention will be given to the ongoing commercial launch of the ClearPoint Prism product offering in the US.   Following the completion of the presentation, viewers will have the

CLS Commercial Partner is Initiating Full Market Release of ClearPoint Prism 3T Neuro Laser Therapy System in The U.S

Lund, Sverige – Clinical Laserthermia Systems AB (publ) (CLS) today announced that its commercial partner, ClearPoint Neuro, Inc (Nasdaq:CLPT), has initiated its full market release of the SmartFrame OR platform and ClearPoint Prism 3T Neuro Laser Therapy System, which is based on CLS’ technology, at the 2024 Biennial Meeting of the American Society of Stereotactic and Functional Neurosurgery taking place June 1-4 in Nashville.­­ Through CLS commercial collaboration with ClearPoint Neuro in neurosurgery an integrated system is offered for MRI image-guided stereotactic laser ablation with

CLS resolves on a partially guaranteed Rights Issue of approximately SEK 59m

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, RUSSIA, BELARUS OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR OTHER MEASURES. PLEASE REFER TO “IMPORTANT INFORMATION” IN THE END OF THIS PRESS RELEASE.   The Board of Directors of Clinical Laserthermia Systems AB AB (publ) ("CLS" or the "Company") has today, with authorization

Correction: CLS publishes interim report January – March 2024

Today, on 29 May at 12:00 CEST, CLS published a press release regarding the publication of the interim report for the first quarter 2024. Unfortunately, the press release contained incorrect information regarding revenue in the CEO comment. The comment stated: "The first quarter of 2024 saw continued growth for CLS. Revenues for the quarter were SEK 2.55 million, which is an increase of 335% compared to the same period last year." The correct information is "The first quarter of 2024 saw continued growth for CLS. Revenues for the quarter were SEK 3.14 million, which is an increase of

CLS publishes interim report January – March 2024

Summary of the interim report (relates to the Group) Three months (01/01/2024–03/31/2024) · Net sales totaled SEK 3,140,000 (SEK 587,000). · Profit/loss after financial items totaled SEK -12,397,000 (SEK -21,464,000). · Basic and diluted earnings per share totaled SEK -0.01 (SEK -0.15). · The equity ratio on March 31, 2024, was 81% (7.5%).Significant events in the first quarter of 2024 · An order for ClearPoint Prism Neuro Laser Therapy System products was received from ClearPoint Neuro, Inc (Nasdaq: CLPT), with an approximate value of SEK 8.1 million. · Mobile

Notice of Annual General Meeting of Clinical Laserthermia Systems AB June 28 2024

The shareholders of Clinical Laserthermia Systems AB, 556705-8903, are hereby invited to an Annual General Meeting on Friday June 28, 2024, at 14:00 CET, Scheelevägen 2, Medicon Village, Lund.Right to participate and registration Shareholders who wish to participate in the Meeting must: · be entered in the share register maintained by Euroclear Sweden AB on Wednesday June 19, 2024, and · register with the company no later than Monday June 24, 2024, in writing to Clinical Laserthermia Systems AB, Medicon Village, Scheelegatan 2, 223 63 Lund. Registration can also be made by phone

BioStock: CLS revises strategy – increases focus on neurosurgery

Clinical Laserthermia Systems revises its strategy to increase the possibility of achieving the goal of reaching a positive cash flow in 2026. The new strategy prioritizes the neurosurgery business area, enabling cost savings of approximately SEK 65 million.– The background to the announced changes to the business is the strength of the ClearPoint Prism product offering, a strength that has become increasingly clear in the spring of 2024 through the initial market launch in the US, CLS writes.Read the full article at biostock.se : https://www.biostock.se/en/

CLS focuses on the Neurosurgery business area to optimize capital allocation, secure profitability targets and implement associated cost savings

Lund, Sverige – Clinical Laserthermia Systems AB (publ) (”CLS” or ”the Company”) today announces that the Company has decided to revise its strategy to increase the possibility to achieve the Company's prioritized goal of reaching a positive cash flow in 2026. The revised strategy means the Company prioritizes and increases its investment in the neurosurgery business area, which is expected to result in significantly improved profitability during the period 2024-2026. The focus on neurosurgery also enables significant cost savings for the Company of approximately SEK 65 million during the

BioStock: CLS launches in France

Clinical Laserthermia Systems has entered into an exclusive distribution agreement with MTEC to market and sell the TRANBERG portfolio in France. The distributor specialises in laser technology and has extensive experience in urology.– The TRANBERG product portfolio perfectly complements our current offering in laser technology in urological oncology, says Eric Girard, CEO of MTEC.Read the full article at biostock.se : https://www.biostock.se/en/2024/05/cls-launches-in-france/ This is a press release from BioStock - Connecting Innovation & Capital. https:

CLS launches its Focal Laser Ablation system for prostate cancer in France in collaboration with MTEC Company

Lund, Sweden, May 14, 2024 – Clinical Laserthermia Systems AB (publ) (“CLS” or “the Company”) today announced it has entered into an exclusive distribution agreement with MTEC Company (“MTEC”) to market and sell the CLS TRANBERG® product portfolio in France.Since December 2023 the TRANBERG system is being used in the French national study IRMPROFT . Based on the growing interest for focal therapies in France, CLS is now entering into an exclusive distribution agreement with MTEC, a national French company with long history and experience

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe